Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pharmacyclics Achieves HDAC Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Pharmacyclics Achieves HDAC Milestone

Pharmacyclics, Inc. has received a $7 million milestone payment from Les Laboratoires Servier (Servier) for its histone deacetylase (HDAC) inhibitor, PCI-24781 / S 78454.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pharmacyclics, Inc. has received a $7 million milestone payment from Les Laboratoires Servier (Servier) for its histone deacetylase (HDAC) inhibitor, PCI-24781 / S 78454. The companies began collaborating in April 2009. Servier has conducted several Phase I/II trials in solid tumors and hematologic malignancies and is now focused on its Phase II programs to establish a registration pathway for PCI-24781 / S 78454.

“Servier is delighted to work with Pharmacyclics under this partnership,” said Emmanuel Canet M.D., Ph.D., Servier’s president, R&D. “The molecule PCI-24781 / S 78454 has performed well in a variety of early stage trials and exceeds our expectations. We plan to further expand the clinical development of PCI-27481 / S 78454.”

Mr. Robert Duggan, Pharmacyclics chief executive officer and chairman, said, “We are very pleased with the progress of PCI-24781 / S 78454 and the alliance with Servier. We are looking forward to work closely with our partner to advance this molecule to the market.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters